EP3325468 - CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 17.09.2021 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 09.10.2020 | ||
Former | Grant of patent is intended Status updated on 04.06.2020 | ||
Former | Examination is in progress Status updated on 11.01.2019 | ||
Former | Request for examination was made Status updated on 27.04.2018 | ||
Former | The international publication has been made Status updated on 27.01.2017 | Most recent event Tooltip | 14.06.2024 | Lapse of the patent in a contracting state New state(s): TR | published on 17.07.2024 [2024/29] | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2020/46] |
Former [2018/22] | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | Inventor(s) | 01 /
STANCATO, Louis Frank c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | [2018/22] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
Former [2020/46] | J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | ||
Former [2018/22] | Smith, Andrew George Eli Lilly and Company Limited European Patent Operations Lilly Research Centre Erl Wood Manor Windlesham, Surrey GU20 6PH / GB | Application number, filing date | 16745005.5 | 15.07.2016 | [2018/22] | WO2016US42529 | Priority number, date | US201562196087P | 23.07.2015 Original published format: US 201562196087 P | US201562248408P | 30.10.2015 Original published format: US 201562248408 P | US201562264059P | 07.12.2015 Original published format: US 201562264059 P | [2018/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017015124 | Date: | 26.01.2017 | Language: | EN | [2017/04] | Type: | A1 Application with search report | No.: | EP3325468 | Date: | 30.05.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.01.2017 takes the place of the publication of the European patent application. | [2018/22] | Type: | B1 Patent specification | No.: | EP3325468 | Date: | 11.11.2020 | Language: | EN | [2020/46] | Search report(s) | International search report - published on: | EP | 26.01.2017 | Classification | IPC: | C07D403/12, A61K31/4155, A61P35/00 | [2018/22] | CPC: |
A61K31/4155 (EP,US);
A61P35/00 (EP,US);
C07D403/12 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/22] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | CHK1/2-INHIBITOREN ZUR BEHANDLUNG VON NEUROBLASTOMEN UND/ODER WEICHGEWEBESARKOMEN | [2018/22] | English: | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | [2018/22] | French: | UTILISATION D'INHIBITEURS DE CHK1/2 DANS LE TRAITEMENT DE NEUROBLASTOMES ET/OU DE SARCOMES DES TISSUS MOUS | [2018/22] | Entry into regional phase | 23.02.2018 | National basic fee paid | 23.02.2018 | Designation fee(s) paid | 23.02.2018 | Examination fee paid | Examination procedure | 01.02.2018 | Amendment by applicant (claims and/or description) | 01.02.2018 | Date on which the examining division has become responsible | 23.02.2018 | Examination requested [2018/22] | 14.01.2019 | Despatch of a communication from the examining division (Time limit: M04) | 23.05.2019 | Reply to a communication from the examining division | 08.07.2019 | Despatch of a communication from the examining division (Time limit: M06) | 16.01.2020 | Reply to a communication from the examining division | 05.06.2020 | Communication of intention to grant the patent | 02.10.2020 | Fee for grant paid | 02.10.2020 | Fee for publishing/printing paid | 02.10.2020 | Receipt of the translation of the claim(s) | Opposition(s) | 12.08.2021 | No opposition filed within time limit [2021/42] | Fees paid | Renewal fee | 31.07.2018 | Renewal fee patent year 03 | 31.07.2019 | Renewal fee patent year 04 | 01.07.2020 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 15.07.2016 | AL | 11.11.2020 | AT | 11.11.2020 | CY | 11.11.2020 | CZ | 11.11.2020 | DK | 11.11.2020 | EE | 11.11.2020 | ES | 11.11.2020 | FI | 11.11.2020 | HR | 11.11.2020 | IT | 11.11.2020 | LT | 11.11.2020 | LV | 11.11.2020 | MC | 11.11.2020 | MK | 11.11.2020 | NL | 11.11.2020 | PL | 11.11.2020 | RO | 11.11.2020 | RS | 11.11.2020 | SE | 11.11.2020 | SI | 11.11.2020 | SK | 11.11.2020 | SM | 11.11.2020 | TR | 11.11.2020 | BG | 11.02.2021 | NO | 11.02.2021 | GR | 12.02.2021 | IS | 11.03.2021 | PT | 11.03.2021 | IE | 15.07.2021 | LU | 15.07.2021 | [2024/29] |
Former [2024/22] | HU | 15.07.2016 | |
AL | 11.11.2020 | ||
AT | 11.11.2020 | ||
CY | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
ES | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
MK | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
IE | 15.07.2021 | ||
LU | 15.07.2021 | ||
Former [2023/30] | HU | 15.07.2016 | |
AL | 11.11.2020 | ||
AT | 11.11.2020 | ||
CY | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
ES | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
IE | 15.07.2021 | ||
LU | 15.07.2021 | ||
Former [2023/28] | HU | 15.07.2016 | |
AL | 11.11.2020 | ||
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
ES | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
IE | 15.07.2021 | ||
LU | 15.07.2021 | ||
Former [2022/35] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
ES | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
IE | 15.07.2021 | ||
LU | 15.07.2021 | ||
Former [2022/23] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
ES | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
LU | 15.07.2021 | ||
Former [2022/18] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
ES | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
PT | 11.03.2021 | ||
Former [2022/10] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
ES | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
PT | 11.03.2021 | ||
Former [2022/08] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
ES | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/50] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/48] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/46] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/45] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/37] | AT | 11.11.2020 | |
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/36] | AT | 11.11.2020 | |
CZ | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/35] | AT | 11.11.2020 | |
CZ | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/34] | AT | 11.11.2020 | |
CZ | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/33] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/32] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/28] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/25] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/23] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
LV | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
PT | 11.03.2021 | ||
Former [2021/22] | FI | 11.11.2020 | |
RS | 11.11.2020 | ||
NO | 11.02.2021 | ||
PT | 11.03.2021 | ||
Former [2021/21] | FI | 11.11.2020 | |
PT | 11.03.2021 | ||
Former [2021/20] | FI | 11.11.2020 | Cited in | International search | [Y]US2005158643 (YAMAGUCHI KIMITOSHI [JP], et al) [Y] 1-55 * paragraphs [0134] , [ 214] * * claims 1,16 *; | [YD]US8314108 (FAROUZ FRANCINE S [US], et al) [YD] 1-55 * column 6, line 15 - column 13, line 49 * * claims 1-8 *; | [Y] - K. A. COLE ET AL, "RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20110222), vol. 108, no. 8, doi:10.1073/pnas.1012351108, ISSN 0027-8424, pages 3336 - 3341, XP055050891 [Y] 1-55 * abstract * DOI: http://dx.doi.org/10.1073/pnas.1012351108 | Examination | WO2006012308 |